A company that lost Tk 147 million last year and has not grown revenue since 2021 just captured the second-highest turnover on the Dhaka Stock Exchange. ACME Pesticides Limited — not a pharmaceutical company, not a bank, not a blue-chip — closed at Tk 27.20 on Monday, up 6.67%, on nearly 10 million shares worth an estimated Tk 268 million. Only City Bank traded more.
The broad market wanted nothing to do with optimism. DSEX shed 15 points to close at 5,232.49, its second consecutive losing session. Of 397 issues traded, 206 declined against 119 advancers. And in the middle of that retreat, a loss-making agricultural chemicals manufacturer under active regulatory scrutiny attracted more capital than all but one listed company in Bangladesh.
That sentence alone should concern you. Here is why it should concern you more.
The Session in Numbers
ACMEPL touched Tk 25.20 early in the session — below its Tk 25.50 previous close — before reversing sharply to reach Tk 27.50, just Tk 0.30 below its 52-week high of Tk 27.80. The stock settled at Tk 27.20 on volume of 9.85 million shares. With 135 million shares outstanding, that means 7.3% of the entire company changed hands in a single day.
The estimated Tk 268 million turnover placed ACMEPL second on the exchange behind City Bank’s Tk 290 million — and ahead of every engineering, textile, and insurance name. ACMEPL alone represented 3.27% of total DSE activity on a day when the exchange processed Tk 820 crore across all issues.
For a company with a market capitalisation of Tk 3.44 billion, that concentration of trading interest is not background noise. It is a signal. The question is what it signals.
The Fundamental Case Against
ACMEPL’s revenue has declined every fiscal year since 2021. From Tk 1.68 billion in FY2021 to Tk 1.59 billion, then Tk 1.20 billion, then Tk 711 million, and finally Tk 482 million in FY2025 — a 71% collapse in top-line revenue across four years. The most recent quarter continued the trajectory: Tk 118 million in revenue, down 27% year-on-year. Trailing EPS sits at negative Tk 1.09. The company pays no dividend.
Against this, the stock has climbed 147% from its 52-week low of Tk 11.00. The 14-day RSI reads 72.67 — technically in overbought territory. The P/E ratio cannot be calculated because there are no earnings to divide into.
When a stock rises 147% while its business shrinks 71%, one of two things is happening: the market knows something the financials do not yet show, or the price has decoupled from reality. The regulatory record suggests which.
Three Flags, No Answers
On April 15 — five trading days before Monday’s session — DSE sent a formal query to ACME Pesticides seeking explanation for unusual trading activity amid a 66% share price surge. As of the query date, the company had not responded publicly.
That exchange-level query followed a more serious development from September 2025: BSEC announced it would seek Anti-Corruption Commission action against 16 ACMEPL shareholders for suspected market manipulation. The list included a former National Board of Revenue member, corporate houses, and institutional investors — the kind of shareholder profile that does not accumulate a mid-cap pesticide stock by accident.
Separately, the High Court has issued a rule against BSEC, DSE, and CSE themselves — for failing to regulate ACME Pesticides over allegations of fraudulent conduct and false statements.
Three regulatory threads running simultaneously. No public response from the company. And 9.85 million shares traded on Monday.
What Fundamentals-Backed Momentum Looks Like
The pharmaceutical sector accounted for 11.8% of total DSE turnover on Monday — the third-largest sector contribution. But ACMEPL is not a pharmaceutical company despite the name confusion. It manufactures pesticides, herbicides, and fertilizers. The genuine pharma momentum story on this exchange belongs to stocks like Asiatic Laboratories.
ASIATICLAB closed at Tk 96.70 on Monday, near its own 52-week high, up 181% over the past year — a chart trajectory that mirrors ACMEPL’s almost exactly. Beneath the chart, almost nothing is similar. ASIATICLAB’s revenue grew 52.2% in the trailing twelve months. Net income reached Tk 378 million. The P/E of 31.14 is demanding but anchored in real earnings growth from a company with 737 employees and over five decades of operating history.
Both stocks surged. One is backed by the strongest revenue growth in its sector. The other is backed by volume.
What Tk 268 Million Is Actually Buying
Monday’s session offered the DSE in miniature. The index fell. Breadth ran bearish. Turnover held at Tk 820 crore — neither panicked nor enthusiastic. And in the middle of a market going nowhere, a single agricultural chemicals company under three layers of regulatory scrutiny captured more turnover than 395 of the 397 stocks on the board.
The market has priced ACMEPL 147% above where it traded a year ago. The regulators have flagged the price action as unusual, the shareholders as suspects, and the company’s disclosures as inadequate. Between the market’s assessment and the regulators’ assessment, one will prove correct.
The Tk 268 million that changed hands on Monday is a bet on which.
Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. Consult a licensed financial adviser before making investment decisions.